SUMMARY: Dengue hemorrhagic fever (DHF) is a severe form of dengue fever (DF). Recent in vitro studies indicate that complement reduces the infection-enhancing activity of dengue antibodies, suggesting its in vivo role in controlling viremia levels and disease severity. In this study, the complement hemolytic activity (CH50) and levels of complement components and related factors in dengue patients in Indonesia were assessed. Based on the number of days since fever onset, DF patients were compared with patients at the DHF pre-critical phase who showed deterioration within 2 days. The mean CH50 values and levels of C2, C4, and factors B and H in the DHF pre-critical phase group were significantly lower than those in the DF group. The mean CH50 values were significantly correlated with C4, factor B, or factor H levels, indicating their responsibility for reduced CH50 values. Furthermore, a significantly higher proportion of the DHF pre-critical phase group (78z) than the DF group (33z) was positive for the nonstructural protein 1 (NS1) antigen. These results suggested that antibody-dependent enhancement of infection occurs during a period of low complement activity, which is associated with NS1 levels during the acute phase in some patients, thereby leading to increased viremia levels and greater disease severity.
INTRODUCTION
Dengue virus (DENV) is widely distributed in the tropical and subtropical areas of the world, causing serious public health problems (1) . DENV causes dengue fever (DF) and its more severe form, dengue hemorrhagic fever (DHF), with an estimated 50-100 million DF cases and 250-500 thousand DHF cases reported annually (2,3). The major symptoms of DF are high fever, headache, muscle and joint pain, and rash. Most patients recover within 1 week after fever onset. In contrast, although the occurrence and progression of DHF are similar to those of DF in the acute phase, symptoms become more severe, and may eventually lead to vascular leakage and shock. The course of DHF is divided into the pre-critical (febrile), critical, and recovery phases (1, 4) . Therefore, DHF patients in the pre-critical phase exhibit symptoms that are usually indistinguishable from those exhibited by DF patients. Many factors reportedly play a role in the process of deterioration in the early phase of DENV infection (5) (6) (7) .
Although the pathogenesis of DHF is not fully understood, disease severity is thought to be correlated with viremia levels (8) (9) (10) . Antibody-dependent enhancement (ADE) of infection is a hypothetical host factor related to increased viremia levels (11) (12) (13) . This mechanism is mediated by Fc gamma receptors on monocytes/macrophages in the presence of non-neutralizing crossreactive antibodies (14) . In contrast, neutralizing antibodies are thought to reduce viremia levels. Thus, enhancing antibodies and neutralizing antibodies play opposite roles in the regulation of viremia levels; because enhancing activities of monoclonal antibodies have been shown at subneutralizing doses, these two opposite activities can be exhibited by one species of antibody depending on the concentration (15) . Mehlhop et al. demonstrated that levels of the complement component C1q were correlated with enhancing activities in in vitro models of dengue type 1 virus and West Nile virus (WNV), depending on the IgG subclass of antibody (16) . Moreover, our previous study revealed that monoclonal antibodies against dengue type 2 and type 4 viruses possess both enhancing and neutralizing activities, depending on the complement activity levels in the assay system (17) .
The complement system plays an important role in protection from infectious diseases (18) . The system has three distinct routes leading to the production of C3 convertases: the classical, lectin, and alternative pathways (19, 20) . The classical pathway is initiated by the reaction of C1q with antibody-antigen complexes, fol-lowed by cascades involving C1r, C1s, C4, and C2 (21) . The lectin pathway is initiated by mannose-binding lectin (MBL), which has a similar structure to that of the C1q-antibody complex and can associate with C4 and C2 (22) . In contrast to these pathways, C3b and factors B (fB) and D (fD) play a major role in the alternative pathway, and the cascade can proceed without C1, C4, or C2 (23) . All three different pathways lead to the production of two distinct C3 convertases: C4b2a (from the classical and lectin pathways) and C3bBb (from the alternative pathway). Although they comprise different constituents, they possess the same enzymatic activity, cleaving C3 to form C3a and C3b. Subsequently, C5 convertases (C4bC2aC3b and C3bBbC3b) can be produced from the C3b and the C3 convertases (C4b2a and C3bBb). The two different C5 convertases have the ability to cleave C5 to generate C5a and C5b. The former is a potent anaphylatoxin (24) . In contrast, C5b is the initial component in the terminal cascade of a series of reactions involving C5b, C6, C7, C8, and C9, which is followed by the formation of the membrane attack complex (MAC: C5b-9) (25) . MAC deeply penetrates into the surface membrane of the cell or enveloped viral particle (26, 27) . In addition, complement regulatory factors, including factors H (fH) and I (fI), are known to inhibit the generation of the C3 convertases (28) .
A few reports have described complement component levels in dengue patients and revealed significantly lower levels in patients with more severe DHF (29, 30) . Some studies have also demonstrated that low complement activity (31) and downregulation of the alternative pathway (32) are associated with DHF, in contrast to most DF patients in whom complement activities are not significantly different from normal (33) . Furthermore, a more recent study reported a contribution of nonstructural protein 1 (NS1)-mediated complement activation to vascular leakage and increased disease severity (34) . However, these reports only utilized patients who already presented DHF symptoms in the critical phase. Thus, the reductions in complement component levels or complement activities described in these reports were most likely due to the deterioration per se. Therefore, it is important to investigate patient status in the DHF pre-critical phase for identifying the factors responsible for deterioration.
In this study, serum samples were collected from dengue patients in Indonesia, and were used to measure the complement hemolytic activity (CH50) and levels of complement components and related factors (C1q, C2, C3, C4, C5, fB, fD, fH, fI, and MBL). The levels of these components were compared between patients grouped according to disease severity. In particular, comparisons were made between the group of DHF patients in the pre-critical phase who subsequently showed deterioration and the group of DF patients who did not exhibit increased disease severity during the course of illness. We also tested the presence of the NS1 antigen, which reportedly circulates at high levels during the acute phase of dengue disease (35, 36) , to examine a potential association with increased disease severity and complement activation. (38) . In brief, DHF I was diagnosed in tourniquet-test-positive patients, DHF II was diagnosed in patients with spontaneous bleeding, DHF III was diagnosed in patients with circulatory failure, and DHF IV was diagnosed in patients with shock diseases. These patients were combined and defined as the DHF group in this study. On the second day of hospitalization during the daily clinical investigations, we found that 18 of the 72 DF patients had developed DHF (the numbers of patients with DHF grades I, II, and III were 9, 3, and 6, respectively). These patients were defined as the DHF pre-critical phase group and were differentiated from the DF group in which the patients did not develop a more severe illness based on daily clinical assessment during hospitalization. Ultimately, 54, 58, and 18 patients were classified into the DF, DHF, and DHF pre-critical phase groups, respectively. The patients in each group were further categorized into subgroups based on the number of days since fever onset (i.e., 3, 4, or 5 days). The numbers of patients in each subgroup as well as their age and gender are shown in Table 2 . Serum samples were collected on average 4.2 days after fever onset, in particular, at 4.1, 4.0, and 4.3 days for the DF, DHF pre-critical phase, and DHF groups, respectively. All patients in the DHF pre-critical phase group developed more severe illness (DHF critical phase) on the second day of hospitalization. Primary or secondary infection was determined using the Panbio Dengue Duo IgM and IgG Capture enzyme-linked immunosorbent assay (ELISA) (Panbio, Sinnamon Park, Australia) following the manufacturer's instructions. IgG and IgM antibody levels were expressed as the ratio of absorbance in serum samples compared with a calibrator. Primary infection was defined as IgM antibody level À1.0 and IgG/IgM antibody ratio º0.5. Secondary infection was defined as IgG antibody level À1.0 and IgG/IgM antibody ratio À1.0 or IgM antibody level º1.0 and IgG antibody level À1.0. As normal controls, 17 serum samples were randomly collected from healthy children (average age, 7.1 years; range, 2-12 years), who visited the hospital for periodical medical examinations. All serum samples were immediately stored at -809 C after collection and handled on ice throughout the measurement process. In particular, the complement activity and levels of C1q, C2, C5, and fB, which are heat-labile components, were rapidly measured with fewer than two freeze and thaw cycles. Complement levels were measured in a blind manner.
MATERIALS AND METHODS
Ethical considerations: The study was approved by Parents of patients or healthy children received a detailed explanation of the present study. Patients, healthy children or their parents, who agreed to the use of their blood samples (Ã3 ml) and the publication of their cases, provided us with signed consent. Measurement of complement activity: Complement hemolytic activities were measured using sheep red blood cells treated with antibodies to sheep red blood cells in the CH50``SEIKEN'' Kit (Denka Seiken, Niigata, Japan) following the manufacturer's instructions and are expressed as a 50z hemolytic unit of complement (CH50 value).
Measurement of levels of individual complement components and related factors: Levels of complement components and related factors (C1q, C2, C3, C4, C5, C5a, fB, fD, fH, fI, and MBL) were measured by a sandwich ELISA. With the exception of C5a, fI, and MBL, microplates (Iwaki, Tokyo, Japan) were incubated with (i) sheep, rabbit, or goat polyclonal antibodies to each complement component (Abcam, Cambridge, UK) or anti-Factor H goat pAb (Merck KGaA, Darmstadt, Germany); (ii) serum samples at 100-100,000-fold dilutions; (iii) mouse monoclonal antibodies to each complement component (Abcam); (iv) rabbit polyclonal secondary antibody to mouse IgG-H&L (HRP) (Abcam) or peroxidase-conjugated Affini- For the measurement of fI, microplates were incubated with (i) goat antisera to human factor I (Quidel, San Diego, Calif., USA); (ii) serum samples; (iii) murine monoclonal anti-human factor I (Quidel); (iv) peroxidase-conjugated AffiniPure Goat Anti-mouse IgG (H ＋ L) (Jackson Immune Research); and (v) TMB substrate. The optical density (OD) was spectrophotometrically measured at a wavelength of 450 nm. For the measurement of MBL, the MBL Oligomer ELISA kit (Bioporto, Gentofte, Denmark) was used following the manufacturer's instructions. For the measurement of C5a, the Human Complement Component C5a DuoSet ELISA Development Kit (R&D Systems, Minneapolis, Minn., USA) was used. The quantity of complement components and related factors was calculated using the forecast function in Microsoft Excel by comparing absorbances with standard curves obtained from serially diluted standard purified human complement components (Merck KGaA) or fI (Quidel) of known concentrations.
The detection ranges were 0-500 mg/ml for C1q, 0-100 mg/ml for C2, 0-3,500 mg/ml for C3, 0-1200 mg/ml for C4, 0-500 mg/ml for C5, 0-600 mg/ml for fB, 0-14 mg/ml for fD, 0-2200 mg/ml for fH, and 0-550 mg/ml for fI.
Measurement of dengue NS1 antigen: The dengue NS1 antigen in serum samples was detected using the Platelia Dengue NS1 Ag ELISA Kit (Bio Rad, Marnesla-Coquette, France) following the manufacturer's instructions. The NS1 antigen levels were expressed as a ratio calculated by the following formula described in the kit instructions: Sample Ratio ＝ OD of sample/OD of the calibrator. For semi-quantification, samples showing ratios of 1.0-5.0 and À5.0 were considered weakly and strongly positive, respectively, for the presence of the NS1 antigen.
Statistical analysis: The statistical significance of differences in complement levels was evaluated using the Mann-Whitney U-test. Correlation coefficients were estimated on the basis of the Pearson product-moment correlation coefficient (R). The association between dengue NS1 antigen levels and disease severity was evaluated using the chi-square test with Yates' correction factor. A probability ( P) value of À0.05 was considered statistically significant.
RESULTS
Low complement activity is correlated with deterioration: To investigate serum complement activity in dengue patients, CH50 values on days 3, 4, and 5 after fever onset were compared between patients grouped on the basis of disease severity on the day of hospitalization (DF and DHF groups) or a time-dependent increase in disease severity (DHF pre-critical phase group). Individual CH50 values on each day are plotted in the 3 left panels of Fig. 1 . Because all patients in the DHF precritical phase group showed deterioration on the day after hospitalization, individual CH50 values obtained on different days after fever onset were combined in each group; these are also plotted in Fig. 1 (rightmost panel) . This panel also includes CH50 values obtained from 17 healthy individuals.
The mean CH50 values in the DHF pre-critical phase group were significantly lower than those in the DF group on any day since fever onset (3 left panels, Fig.  1 ). We also observed a significant difference in mean CH50 values between the DHF pre-critical phase and DHF groups on day 5. When data obtained on days 3-5 were combined (rightmost panel, Fig. 1 ), the ranges of individual CH50 values in the DF and healthy groups were 12-112 U/ml and 31-129 U/ml, respectively, whereas that in the DHF pre-critical phase group was 4-42 U/ml. The mean CH50 value in the DHF pre-critical phase group (30 U/ml) was significantly lower than those in the DF (60 U/ml; P º 0.001) and healthy (63 U/ml; P º 0.001) groups. There was no significant difference in mean CH50 values between the DF and healthy groups ( P À 0.05). In addition, the mean CH50 value in the DHF pre-critical phase group was significantly lower than that in the DHF (46 U/ml; P º 0.001) group. When the DHF group was divided into group. The bar represents the average for each group. Probability levels ( P) less than 0.05 were considered statistically significant and are indicated in the graph: * , P º 0.05; †, P º 0.01; ‡, P º 0.001. Fig. 2 . Comparison of C1q, C2 and C4 levels. Individual levels of C1q, C2 and C4 for each of the DF (diamond), DHF precritical phase (PCP: circle) and DHF (triangle) groups at 3, 4 and 5 days after fever onset (3 left upper, middle and lower panels) are plotted. The rightmost panels indicate individual levels obtained from the combined populations on days 3-5, including the healthy (Hlth; square) group. The bar represents the average for each group. For comparisons among patient groups, probability levels (P ) less than 0.05 were considered statistically significant and are indicated in the graph: * , P º 0.05; †, P º 0.01; ‡, P º 0.001. A section sign ( §) close to the average bar in the healthy group indicates that the mean was significantly higher than that obtained for each patient group. and 5 days after fever onset (3 left upper, and lower panels) are plotted. The rightmost panels indicate individual levels obtained from the combined populations on days 3-5, including the healthy (Hlth; square) group. The bar represents the average for each group. For comparisons among patient groups, probability levels ( P) less than 0.05 were considered statistically significant and are indicated in the graph: * , P º 0.05; †, P º 0.01. When the mean in the healthy group was significantly higher than those in each patient group, a section sign ( §) is indicated near the average bar in the healthy group.
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grades I-IV, no significant differences in mean CH50 values were observed among these grades; however, the value obtained from the combined population of grades III and IV was significantly lower than that obtained from the combined population of grades I and II ( P º 0.05; data not shown). These results indicated that low serum complement activity was correlated with the subsequent increase in disease severity in the present patient population.
Relationship between complement component levels and disease severity: Because the CH50 values were found to be different between the DF and DHF pre-critical phase groups, we measured the levels of complement components and related factors (C1q, C2, C4, fB, fD, fH, fI, and MBL) using the same serum samples used in the above experiment to identify the complement components and pathways related to deterioration. Individual data of the DF, DHF pre-critical phase, DHF, and healthy groups are shown in Figs. 2-4 ; data separated on the basis of the number of days since fever onset are shown in the 3 left panels, while combined data are shown in the rightmost panel.
Complement components C1q, C2, and C4 are the major components of the classical pathway, one of the three pathways involved in the early phase of the complement activation process. The levels of these complement components in patient sera are shown in Fig. 2 . Although mean C1q levels in the patient groups were significantly lower than that in the healthy group, there was no significant difference among the patient groups (rightmost upper panel, Fig. 2 ). In contrast, mean levels of C2 and C4 in the DHF pre-critical phase group were significantly lower than those in the DF and DHF groups (rightmost middle and lower panels, Fig. 2) . When analyzed by the number of days since fever onset (3 left middle and lower panels, Fig. 2 ), significant differences in mean C2 or C4 levels between the DHF pre-critical phase and DF groups were observed on days 3 and/or 4. We also observed significant differences in C2 (day 4) or C4 (days 3 and 4) levels between the DHF pre-critical phase and DHF groups. When the DHF group was divided into grades I-IV, the C4 level obtained from those with grades III/IV was significantly lower than that obtained from those with grades I/II. These results suggested that low levels of C2 and C4 were correlated with increased disease severity.
The major complement components of the alternative pathway are fB and fD. Although there was no significant difference in mean fD levels among the patient groups, the mean fB level in the DHF pre-critical phase group was significantly lower than that in the DF group (rightmost panels, Fig. 3 ). When analyzed by the number of days since fever onset (3 left upper and lower panels, Fig. 3) , the mean fB level in the DHF pre-critical phase group was significantly lower than that in the DF group on days 3 and 4. These results suggested that the alternative pathway is also involved in the deterioration of dengue disease and that fB may play an important role in this process.
MBL is a key protein in the lectin pathway and triggers complement activation via an antibody-independent mechanism. A comparison of MBL levels revealed that the ranges of individual levels were similar and the The rightmost panels indicate individual levels obtained from the combined populations on days 3-5, including the healthy (Hlth; square) group. The bar represents the average for each group. Probability levels ( P) less than 0.05 were considered statistically significant and are indicated in the graph: *, P º 0.05. 3) : Significantly higher than 26z of the DF group ( P º 0.05) obtained on day 4. 4) : Significantly higher than 33z and 31z of the DF and DHF groups, respectively ( P º 0.01), obtained in the total population. 5) : Positivity in the primary infection type was significantly higher than that in the secondary type ( P º 0.01). 6) : Positivity in the primary infection type was significantly higher than that in the secondary type ( P º 0.05).
371 mean levels were not significantly different among the DHF pre-critical phase, DF, and healthy groups (data not shown). These results indicated that, in contrast to the classical and alternative pathways, the lectin pathway is not important for deterioration in dengue patients. The levels of complement regulatory factors (fH and fI) were also measured (Fig. 4) . The mean level of fH, which regulates the alternative pathway, in the DHF pre-critical phase group, was significantly lower than that in the DF group ( P º 0.05) (rightmost upper panel, Fig. 4) . When analyzed on each fever day (3 left upper panels, Fig. 4 ), a significant difference in mean fH levels between the DHF pre-critical phase and DF groups was observed on day 4. The fI can regulate not only the alternative pathway but also the classical pathway. As shown in the lower panels of Fig. 4 , there was no significant difference in the fI levels among the patient groups.
Correlation between CH50 values and complement component levels: To identify the components responsible for the low complement activity in the DHF pre-critical phase group, correlation coefficients between CH50 values and the level of each complement component were calculated using 130 individual values obtained from all the DF, DHF pre-critical phase, and DHF groups (Fig. 5 ). Significant correlations were observed for C4 (0.257; P º 0.01), fB (0.306; P º 0.001), and fH (0.236; P º 0.01). These results indicated that the C4, fB, and fH levels were directly related to the complement activity in sera from dengue patients and supported the possibility that the low CH50 level in dengue patients, particularly in the DHF pre-critical phase Fig. 6 . Semiquantitative DENV NS1 antigen levels in relation to complement activity. The mean CH50 values in patients strongly positive (＋＋), weakly positive (＋) and negative (-) for NS1 antigen were calculated for each of the DF, DHF precritical phase (PCP) and DHF groups. For calculation of mean CH50 values in the DHF group, data obtained on day 5 after fever onset were excluded (see text). Probability levels (P) less than 0.05 were considered statistically significant and are indicated in the graph: * , P º 0.05; †, P º 0.01.
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group, was attributable to a decreased level of complement components in the classical and alternative pathways. Semiquantitative DENV NS1 antigen levels relate to disease severity and complement activity: DENV NS1 antigen levels were semiquantitatively measured in 130 patients and analyzed with respect to disease severity (Table 3 ). Overall, 78z of patients in the DHF pre-critical phase group (14 of 18 patients) were either weakly or strongly positive for the NS1 antigen, which was significantly higher than the proportions of DF (33z, 18 of 54 patients; P º 0.01) and DHF (31z, 18 of 58 patients; P º 0.01) patients showing such positivity. When the comparison was made on the basis of the number of days since fever onset, significant differences were observed on day 4: the proportion of NS1-positive patients in the DHF pre-critical phase group (75z, six of eight) was significantly higher than that in the DF group (26z, nine of 34; P º 0.05). However, there were no significant differences in the proportions of NS1 antigen-positive patients between the DF and DHF groups. This result suggested that the presence of the NS1 antigen was associated with disease severity.
No significant differences in DENV NS1 antigen positivity were observed between patients with primary and secondary infections, except in the DHF group on day 5 and the combined population on days 3-5, where patients with primary infection showed a significantly higher degree of antigen positivity (64z and 52z, respectively) than those with secondary infection (6z and 19z; P º 0.01 and P º 0.05, respectively) ( Table 3 ). The significant difference between patients with primary and secondary infections in the DHF group on day 5 suggested an effect of the anti-NS1 antibody on the NS1 antigen assay system.
To investigate a possible effect of the NS1 antigen on complement activity in sera, mean CH50 values and semiquantitative NS1 antigen levels were compared (Fig. 6) . The comparison was made separately for each of the DF, DHF pre-critical phase, and DHF groups, because the mean CH50 value in the DHF pre-critical phase group was significantly lower than those in the DF and DHF groups, as shown in Fig. 1 . In the DHF group, data obtained on day 5, when significantly different NS1 positivity was observed between the patients with primary and secondary infections (Table  3) , were excluded from analysis. In all the groups (Fig.  6 ), mean CH50 values in patients who were strongly positive for the NS1 antigen were significantly lower than those in NS1-negative patients ( P º 0.05 or P º 0.01). In addition, the mean CH50 value in patients weakly positive for the NS1 antigen was significantly lower than that in NS1-negative patients in the DF group ( P º 0.05). Although no significant differences in CH50 values were observed between weakly positive and negative patients in the DHF pre-critical phase and DHF groups, the differences between weakly and strongly positive patients were significant in these groups ( P º 0.01). These results suggested a relationship between complement activity and the presence of the NS1 antigen in patient sera.
DISCUSSION
In the early phase of DHF, the symptoms are very similar to those associated with DF. The timing of deterioration differs among individuals. In the present study, DHF pre-critical phase and DF groups with the same number of days since fever onset were compared as part of a unique approach to identify factors related to the deterioration process. Previous studies have demonstrated low complement activity and levels using samples obtained only after deterioration had already occurred (29) (30) (31) 34) . In our results, the DHF pre-critical phase group showed significantly lower mean complement activities (Fig. 1) and C2, C4, fB, and fH levels (Figs. 2-4) , among which C4, fB, and fH showed significant correlations with mean CH50 values (Fig. 5) . Although data are not shown, significant differences obtained for these activities/factors were consistently shown in patients with secondary infection. These results indicated that the activation of the classical and alternative pathways during the early stage of illness is correlated with reduced serum CH50 values, which may predispose patients to subsequent deterioration. Although significant differences were observed in CH50 values and some complement component levels when means were compared between the DF and DHF pre-critical phase groups, relatively wide individual variations were also observed. Thus, complement is not the only potential factor involved in deterioration, and a particular combination with other proposed factors (7) may ultimately be involved. Interestingly, among the complement components proposed in our study, C2, C4, and fB are encoded on human chromosome 6 (39), suggesting that the genomic clustering of these components may regulate their expression.
The C1 complex is composed of C1q, C1r, and C1s. C1q is the initial component in the classical pathway, and directly binds to antibody-antigen complexes. Activation of the C1 complex leads to the cleavage of C4 and C2, resulting in the generation of C4b2a (21) . Therefore, measurement of the C1q level is important to allow observation of the initial step of classical pathway activation. The results of a previous in vivo study sug-gested that the C1q level is correlated with disease severity in dengue patients (40) . Recent in vitro studies have demonstrated that the presence of C1q in the assay system affects the ADE activities of anti-dengue antibodies (16, 17) , suggesting an important role of C1q in the ADE phenomenon. In addition, increased levels of immune complexes have been reported in dengue patients (41) , and these result in the activation of C1q. The present study also indicated C1q activation in the patient groups; however, no detectable significant difference was observed between the DF and DHF precritical phase groups, despite C2 and C4 activation in the DHF pre-critical phase group (Fig. 2) . This contradiction could be explained by the finding that NS1 associates with C1s and C4 and reduces complement activity (42) . Thus, we supposed that C4 was activated by synergistic reactions initiated by C1q and NS1, in which NS1 was more likely to play an important role in C4 activation, because there was a correlation between the NS1 level and CH50 value (Fig. 6) .
The activation of the classical and alternative pathways generates C3 convertases (C4b2a and C3bBb) and cleaves C3. The product C3b activates C5 to proceed to the terminal pathway, generating MAC. A correlation between C3 levels and dengue disease severity has been reported (29, 30, 43, 44) . In this study, stronger activation of the classical (Fig. 2) and alternative (Fig. 3) pathways was observed in the DHF pre-critical phase group than in the DF group. However, attempts to demonstrate differences in C3, C5, or C5a levels between the DHF pre-critical phase and DF groups have been unsuccessful (data not shown), possibly owing to wide individual differences. Nevertheless, low levels of C2, C4, fB, and fH, among which C4, fB, and fH showed significant correlations with CH50 values, suggested the existence of reduced MAC activities in the DHF pre-critical phase group.
The involvement of the alternative pathway in disease severity was examined by another group who showed that a lack of alternative pathway regulation by fD and fH is correlated with DHF (32); however, these authors did not demonstrate a role for fB in the alternative pathway. In this study, low levels of fB and fH were correlated with deterioration ( Figs. 3 and 4) ; however, there was no significant difference in fD levels between the DHF pre-critical phase and DF groups (Fig. 3) . Moreover, another study showed that the soluble NS1 protein of the WNV bound to fH and enhanced its regulatory activity (45) . This phenomenon reported for WNV may explain our finding for DENV with a lower fH level in the DHF pre-critical phase group than in the DF group (Fig. 4) because increased NS1 antigen positivity was shown in the DHF pre-critical phase group (Table 3) .
CH50 values in the DHF pre-critical phase group were lower than those in the DF group regardless of the number of days since fever onset (Fig. 1) . A comparison of complement levels indicated that low levels of C2, C4, fB, and fH in the DHF pre-critical phase group were observed on days 3 and/or 4 (Figs. 2-4) . These results suggested that measurement of the complement profile in the acute phase could contribute to predictions of subsequent disease severity. In particular, three complement components (C4, fB, and fH), the levels of which showed correlations with CH50 values (Fig. 5) , may be useful as predictors of disease severity.
While the complement system plays a protective role against infectious diseases, it also contributes to pathogenesis (46). Avirutnan et al. (34) showed that NS1 activates complement and byproducts such as anaphylatoxins and that MAC may contribute to vascular leakage in DHF patients, in whom plasma NS1 levels were correlated with disease severity. In addition, a recent in vitro study demonstrated that NS1 binds C1s and C4 to antagonize complement activation (42) . Consistently, our present study showed lower CH50 values and lower levels of complement components, including C4, in the DHF pre-critical phase group, which had a higher proportion of NS1 antigen-positive patients, than the DF group. However, a group reported a reverse correlation (higher NS1 antigen positivity rates in DF patients) (47) ; it is possible that various factors (e.g., timing of sample collection, race, age, and immune status) affected the results.
In conclusion, we showed that, irrespective of the number of days since fever onset, complement activities in the group of patients who developed DHF the day after hospitalization were lower than those in the DF group patients who recovered without deterioration. Low levels of C2, C4, fB, and fH were observed in patients in the DHF pre-critical phase group, and C4, fB, and fH were found to be responsible for the reduced complement activity. We also showed an association of NS1 levels with complement activities and disease severity, supporting the possible existence of a relationship between low complement activities and subsequent progression to DHF. Thus, one hypothesis derived from these results would be that ADE induced under a low complement condition in some acute patients may be correlated with subsequent increased viremia levels and disease severity. On the other hand, the present findings may be limited to pediatric cases because of the differences in clinical manifestations and complement activities between children and adults.
